Get started
Author

Scott F. Huntington

Observed names: S. F. Huntington, S. Huntington, S.F. Huntington, Scott F Huntington, Scott Huntington
Observed institutions: Yale New Haven Hospital, Memorial Sloan Kettering Cancer Center, Hospital of the University of Pennsylvania, Yale Cancer Center, Yale University, Smilow Cancer Hospital, Weill Cornell Medicine, Abramson Cancer Center, University of Pennsylvania, Vanderbilt University Medical Center
ORCID: 0000-0001-7071-6475
Observed ORCID: 0000-0001-7071-6475
OpenAlex ID: A5035304428
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
2020 · Anthony R. Mato, Lindsey E. Roeker, et al. · Blood · 305
PDF
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study
2015 · Scott F Huntington, Brendan M Weiss, et al. · The Lancet Haematology · 216
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
2015 · Andrew G. Evans, Paul G. Rothberg, et al. · British Journal of Haematology · 104
PDF
R‐ CHOP versus dose‐adjusted R‐ EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis
2017 · Nirav N. Shah, Aniko Szabo, et al. · British Journal of Haematology · 103
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
2021 · Victor Manuel Orellana-Noia, Daniel R. Reed, et al. · Blood · 94
PDF
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
2020 · Amer M. Zeidan, Rong Wang, et al. · Blood Advances · 92
PDF
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients
2020 · Mengyang Di, Scott F Huntington, et al. · The Oncologist · 81
PDF
Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life
2017 · Rong Wang, Amer M. Zeidan, et al. · Journal of Clinical Oncology · 77
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
2016 · Amer M. Zeidan, Amy J. Davidoff, et al. · British Journal of Haematology · 72
PDF
Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission
2015 · Scott F. Huntington, Jakub Svoboda, et al. · Journal of Clinical Oncology · 69
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
2021 · Lindsey E. Roeker, Toby A. Eyre, et al. · Blood · 66
PDF
Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
2018 · Amer M. Zeidan, Maximilian Stahl, et al. · Blood Cancer Journal · 62
PDF
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
2017 · Amer M. Zeidan, Maximilian Stahl, et al. · Blood · 61
PDF
Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States
2020 · Amer M. Zeidan, Nikolai A. Podoltsev, et al. · Blood Advances · 56
PDF
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
2022 · Kunal C. Potnis, Mengyang Di, et al. · Blood Advances · 54
Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study
2020 · John G. Gribben, Wojciech Jurczak, et al. · Blood · 54
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
2020 · Smith Giri, Scott F. Huntington, et al. · Blood Advances · 53
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
2018 · Scott F. Huntington, Gottfried von Keudell, et al. · Journal of Clinical Oncology · 50
Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma
2021 · Kishan K. Patel, Smith Giri, et al. · Journal of Clinical Oncology · 43
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
2020 · Kishan K. Patel, Iris Isufi, et al. · Blood · 41
Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis
2018 · Steven M. Bair, Lauren E. Strelec, et al. · The Oncologist · 41
PDF
Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis
2019 · Amer M. Zeidan, Nikolai A. Podoltsev, et al. · Cancer · 40
High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
2016 · Jalpa A Doshi, Pengxiang Li, et al. · PubMed · 38
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
2021 · Kishan K. Patel, Amer M. Zeidan, et al. · Blood Advances · 36
Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
2019 · Pau Abrisqueta, Juan-Manuel Sancho, et al. · Blood · 36
Works count: 269
Citation count: 3,021
H-index: 28
I10-index: 68
Year
Topic
Type